MarketCapExport financials
Eagle Pharmaceuticals (EGRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Eagle Pharmaceuticals Income Statement 2022-2011 | EGRX
Brief overview of profit and loss at Eagle Pharmaceuticals
The overview follows changes across a five-year period. The revenue attributed to Eagle Pharmaceuticals moved from $237 million to $317 million between the two endpoints. Across the full period, sales moved by +33.8%; the average annual rate was 6%. The company expanded at a measured pace.
At the gross-profit level, the result moved from 180 million dollars to 231 million dollars, a change of +28.8%. The relationship between sales and direct costs deteriorated. Comparing the endpoints gives gross margins of 75.8% and 73%. A lower margin indicates deterioration in the economics of the core business.
The operating result measured by EBITDA moved from $74.9 million to $81.6 million, or +8.9%. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from 31.7% to 25.8%. Operating return per unit of revenue declined.
The five-year change in net income was −31.4%: from 51.9 million dollars to 35.6 million dollars. The business generated less net income by the end of the period.
Over the period, capitalization shifted from $903 million to $340 million (−62.3%). The decline in value indicates softer investor confidence.
Summary assessment
The results contain several connected negative signals. The financial profile benefits from revenue expansion. The main areas of concern are a weaker market valuation, weaker operating efficiency and declining net profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
340 M | 600 M | 629 M | 740 M | 624 M | 903 M | 1.08 B | 1.1 B | 272 M | - | - | - |
Shares |
12.9 M | 13.1 M | 13.5 M | 13.8 M | 14.8 M | 15.1 M | 15.5 M | 15.3 M | 14 M | 3.04 M | 1.65 M | - |
Historical Prices |
26.3 | 45.9 | 46.7 | 53.8 | 42.3 | 59.8 | 69.2 | 71.9 | 19.4 | - | - | - |
Net Income |
35.6 M | -8.63 M | 12 M | 14.3 M | 31.9 M | 51.9 M | 81.5 M | 2.57 M | -5.51 M | -3.26 M | -19.4 M | - |
Revenue |
317 M | 172 M | 188 M | 196 M | 213 M | 237 M | 189 M | 66.2 M | 19.1 M | 13.7 M | 2.54 M | - |
Cost of Revenue |
85.5 M | 31.5 M | 33.6 M | 47.9 M | 42.4 M | 33.7 M | 35.8 M | 15.6 M | 1.78 M | 2.67 M | 3.17 M | - |
Gross Profit |
- | - | - | 36.7 M | 37.5 M | 180 M | 134 M | 50.6 M | 7.38 M | 6.3 M | -627 K | - |
Operating Income |
81 M | 2.77 M | 33 M | 21.8 M | 36.6 M | 74 M | 53.4 M | 2.56 M | -6.56 M | -3.06 M | -19.8 M | - |
Interest Expense |
4.04 M | 1.64 M | 2.58 M | 2.69 M | 2.74 M | 1.14 M | 8 K | 11 K | 1 K | 309 K | 91 K | - |
EBITDA |
81.6 M | 3.53 M | 33.8 M | 22.8 M | 37.8 M | 74.9 M | 54 M | 2.67 M | -6.55 M | -2.93 M | -19.6 M | - |
Operating Expenses |
- | - | - | 113 M | 177 M | 163 M | 136 M | 63.7 M | 12.2 M | 8.56 M | 22.4 M | - |
General and Administrative Expenses |
107 M | 75.3 M | 78.6 M | 76.4 M | 60.5 M | 71.4 M | 53.3 M | 20.2 M | 3.69 M | 1.34 M | 6.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
13.1 M | 13.1 M | - | 13.2 M | 12.8 M | 12.7 M | - | 13.1 M | 13.1 M | 13.1 M | - | 13.5 M | 13.7 M | 13.7 M | - | 13.7 M | 13.8 M | 13.9 M | - | 15 M | 14.9 M | 14.8 M | 14.8 M | 15 M | 15.2 M | 15.3 M | - | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.5 M | 14.2 M | 14 M | 14 M | 8.86 M | 8.86 M | 3.05 M | 3.02 M | 3.05 M | 3.05 M | - | - | - | - | - | - | - | - |
Net Income |
5.16 M | 5.75 M | - | -7.13 M | -9.45 M | 44.1 M | - | -5.62 M | 3.61 M | -421 K | - | 7.06 M | -256 K | -2.87 M | - | -2.39 M | 6.72 M | 8.97 M | - | 14 M | 2.66 M | 2.62 M | - | 15.4 M | 4.5 M | 22.9 M | - | 12 M | 13.1 M | -896 K | 1.22 M | -10.2 M | -8.18 M | 19.7 M | -5.51 M | -2.93 M | -2.68 M | -2.68 M | -3.26 M | -6.53 M | 755 K | -4.8 M | - | - | - | - | - | - | - | - |
Revenue |
64.6 M | 66.3 M | - | 65.9 M | 74.1 M | 116 M | - | 39.9 M | 48.1 M | 41.2 M | - | 49.9 M | 41.9 M | 46 M | 48.3 M | 41.1 M | 56.7 M | 49.8 M | 56.1 M | 51.3 M | 59.3 M | 46.6 M | 46.8 M | 63 M | 50.1 M | 76.8 M | 81.1 M | 37.8 M | 40.9 M | 29.6 M | 18.2 M | 5.74 M | 6 M | 36.3 M | 5.6 M | 2.81 M | 5.79 M | 5 M | 5.49 M | 9.04 M | 5.08 M | 2.48 M | - | - | - | - | - | - | - | - |
Cost of Revenue |
16.9 M | 17.3 M | - | 20.9 M | 21.2 M | 25.2 M | - | 5.49 M | 7.91 M | 8.44 M | - | 8.73 M | 10.3 M | 4.76 M | - | 12.1 M | 18.2 M | 9.55 M | - | 8.62 M | 14.1 M | 7.22 M | - | 4.82 M | 8.91 M | - | - | 10.4 M | 11.5 M | 14.6 M | - | 3.75 M | 3.35 M | 5.95 M | 1.78 M | 1.56 M | 3.36 M | 3.36 M | 2.67 M | 4.45 M | 2.93 M | 1.31 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.7 M | 26.2 M | 35.4 M | 36.7 M | 37.5 M | 38.3 M | 40.7 M | 34.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
10.3 M | 11.8 M | - | 9.46 M | 2.2 M | 59.8 M | - | -10.2 M | 10.8 M | -3.77 M | - | 15.4 M | 3.71 M | 4.04 M | 2.9 M | -2.48 M | 9.23 M | 12.2 M | 15.7 M | 18.4 M | 183 K | 2.3 M | 10.4 M | 25 M | 5.9 M | 32.7 M | 28.3 M | 12.3 M | 13.7 M | -897 K | 1.19 M | -10.4 M | -8.34 M | 20.1 M | -6.56 M | -2.98 M | -3.6 M | -3.6 M | -3.06 M | -5.92 M | 1.26 M | -4.31 M | - | - | - | - | - | - | - | - |
Interest Expense |
1.45 M | 1.52 M | - | 1.15 M | 552 K | 366 K | - | 396 K | 422 K | 422 K | - | 489 K | 786 K | 889 K | - | 628 K | 665 K | 686 K | - | 743 K | 701 K | 675 K | - | 527 K | 66 K | 27 K | - | 3 K | 3 K | 1 K | - | 5 K | 3 K | 1 K | 1 K | 4.81 K | 1.43 K | 1 K | - | 309 K | 16 K | 145 K | - | - | - | - | - | - | - | - |
EBITDA |
10.4 M | 11.9 M | - | 9.66 M | 2.4 M | 60 M | - | -9.98 M | 11 M | -3.58 M | - | 15.6 M | 3.92 M | 4.29 M | 2.9 M | -1 M | 10.2 M | 12.7 M | 15.7 M | 19.3 M | 866 K | 2.65 M | 10.4 M | 25.6 M | 6.33 M | 32.9 M | 28.3 M | 12.8 M | 14 M | -757 K | 1.19 M | -10.4 M | -8.31 M | 20.1 M | -6.55 M | -2.9 M | -3.54 M | -3.57 M | -3.03 M | -5.82 M | 1.34 M | -4.31 M | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.6 M | 47.5 M | 37.6 M | - | 32.9 M | 59.1 M | 44.3 M | - | 38.1 M | 44.2 M | 44.1 M | - | 25.5 M | 27.3 M | 30.5 M | - | 16.1 M | 14.3 M | 16.2 M | 12.2 M | 8.77 M | 8.61 M | 8.61 M | 8.56 M | 15 M | 3.82 M | 6.79 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
27.7 M | 28 M | - | 23.5 M | 36.8 M | 22.2 M | - | 18.5 M | 16.6 M | 19.9 M | - | 17.7 M | 18 M | 24.8 M | - | 18.5 M | 17.2 M | 18.1 M | - | 13.9 M | 16 M | 15.2 M | - | 16.7 M | 23.7 M | 18.6 M | - | 11.9 M | 12.1 M | 11 M | - | 5.46 M | 5.11 M | 3.99 M | 3.69 M | 2.67 M | 1.45 M | 1.45 M | 1.34 M | 6.13 M | 1.25 M | 2.95 M | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Eagle Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
Irlanda
Canada
China
Schweden
